Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

BACKGROUND: It is unclear what to do when people with type 2 diabetes have had no or a limited glycemic response to a recently introduced medication. Intra-individual HbA1c variability can obscure true response. Some guidelines suggest stopping apparently ineffective therapy, but no studies have addressed this issue. METHODS: In a retrospective cohort analysis using the UK Clinical Practice Research Datalink (CPRD), we assessed the outcome of 55,530 patients with type 2 diabetes starting their second or third non-insulin glucose-lowering medication, with a baseline HbA1c > 58 mmol/mol (7.5%). For those with no HbA1c improvement or a limited response at 6 months (HbA1c fall

Original publication

DOI

10.1186/s12916-019-1307-8

Type

Journal article

Journal

BMC Med

Publication Date

12/04/2019

Volume

17

Keywords

Addition, Continuation, Glycemic control, HbA1c, Oral glucose-lowering medication, Switching, Type 2 diabetes, Adult, Aged, Cohort Studies, Diabetes Mellitus, Type 2, Female, Glycated Hemoglobin A, Humans, Hypoglycemic Agents, Male, Middle Aged, Retrospective Studies